Transgene S.A.
TNG
Rank in Stocks
#16049
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Share Price
$0.8271141
Last synced: 2026-11-09
Market Cap
$230.15M
Change (1 day)
-0.81%
Change (1 year)
-43.99%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Transgene S.A. (TNG)
Category
Healthcare
Operating Margin for Transgene S.A. (TNG)
Operating Margin as of November 2026 TTM: -12,438.98%
According to Transgene S.A.'s latest financial reports, its current operating margin (TTM) is -12,438.98%. At the end of 2025 the company had an operating margin of -8,381.63%.
Operating Margin history for Transgene S.A. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -12,438.98% | 48.41% |
| 2025 | -8,381.63% | 1,393.31% |
| 2024 | -561.28% | 47.57% |
| 2023 | -380.34% | -60.24% |
| 2022 | -956.62% | 306.36% |
| 2021 | -235.41% | -70.75% |
| 2020 | -804.86% | 320.42% |
| 2019 | -191.44% | -134.69% |
| 2018 | 551.91% | -141.31% |
| 2017 | -1,336.02% | 38.29% |
| 2016 | -966.07% | -60.47% |
| 2015 | -2,444.16% | 29.68% |
| 2014 | -1,884.82% | 76.09% |
| 2013 | -1,070.36% | -0.22% |
| 2012 | -1,072.68% | 245.68% |
| 2011 | -310.31% | 26.54% |
| 2010 | -245.22% | 5.54% |
| 2009 | -232.34% | 47.62% |
| 2008 | -157.39% | 491.25% |
| 2007 | -26.62% | -93.44% |
| 2006 | -405.95% | -52.90% |
| 2004 | -861.97% | -1.72% |
| 2003 | -877.09% | -5.06% |
| 2002 | -923.80% | -52.14% |
| 2001 | -1,930.40% | 269.39% |
| 2000 | -522.59% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -99.99% |
US
|
|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Transgene S.A.'s operating margin
What is Transgene S.A.'s operating margin?
Transgene S.A.'s operating margin is -12,438.98%, as of Nov 2026.
What was Transgene S.A.'s operating margin in 2025?
In 2025, Transgene S.A.'s operating margin was -8,381.63%, compared with -561.28% in 2024.
How has Transgene S.A.'s operating margin changed since 2020?
From 2020 to 2025, Transgene S.A.'s operating margin was highest in 2021 (-235.41%) and lowest in 2025 (-8,381.63%).
How does Transgene S.A.'s operating margin compare with similar companies?
Transgene S.A.'s operating margin (-12,438.98%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.